Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
siRNA
Biotech
AstraZeneca FLAP inhibitor flunks ph. 2 asthma trial
AstraZeneca has scrapped an asthma program after the FLAP inhibitor flunked a phase 2 trial.
James Waldron
Apr 29, 2026 8:38am
The 'diabolical' molecule set to become biotech's next gold rush
Apr 9, 2026 8:00am
Wave crashes after obesity trial tracks 1% dip in body weight
Mar 26, 2026 9:20am
Sarepta's big bet on Arrowhead's siRNA assets yields early data
Mar 25, 2026 9:35am
Atrium arises from Avidity buyout with $270M, preclinical assets
Feb 27, 2026 11:05am
GSK explores frontiers of siRNA with $1B deal for 2 drugs
Feb 24, 2026 8:10am
